Skip to main content
. 2018 Jan 16;27(6):969–984. doi: 10.1093/hmg/ddy013

Table 1.

List of the CFTR correctors with concentrations utilized in this study

CFF namea Original name Compoundb IUPAC name Concentration µM
C2 VRT-640c C 2-{1-[4-(4-Chloro-benzensulfonyl)-piperazin-1-yl]-ethyl}-4-piperidin-1-yl-quinazoline 5
C3 VRT-325d B 4-Cyclohexyloxy-2-{1-[4-(4-methoxy-benzensulfonyl)-piperazin-1-yl]-ethyl}-quinazoline 10
C5 corr 5ae H 4, 5, 7-trimethyl-N-phenylquinolin-2-amine 15
C6 corr 5ce I N-(4-bromophenyl)-4-methylquinolin-2-amine 10
C9 KM11060f F 7-chloro-4-(4-(4-chlorophenyl sulfonyl)piperazin-1-yl)quinoline 10
C4 corr 4ae E N-[2-(5-Chloro-2-methoxy-phenylamino)-4'-methyl-[4, 5']bithiazolyl-2'-yl]-benzamide 10
C13 corr 4ce Q N-(2-(3-acetylphenylamino)-4'-methyl-4, 5'-bithiazol-2'-yl)benzamide 5
C14 corr 4de R N-(2'-(2-methoxyphenylamino)-4-methyl-5, 5'-bithiazol-2-yl)benzamide 5
C17 15jfg A N-(2-(5-chloro-2-methoxyphenylamino)-4'-methyl-4, 5'-bithiazol-2'-yl)pivalamide 2
C15 corr 2be S N-phenyl-4-(4-vinylphenyl)thiazol-2-amine 15
VX809h Lumacaftor U 3 -(6-(I -(2, 2- difluorobenzo[d][l, 3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid 6
Glafeninei 2, 3-dihydroxypropyl 2-[(7-chloroquinolin-4-yl)amino]benzoate 10
a

Name according to the list of the Cystic Fibrosis Foundation [https://www.cff.org/CFTR-Chemical-Compound.pdf].

b

Name according to [WO2014086687].

c

WO2004111014 A.

d

US20050059687 A1.

e

Pedemonte et al. (2005) (15).

f

Robert et al. (2008) (20).

g

Yoo et al. (2008) (21).

h

US2011257223.

i

Robert et al. (2010) (22).